POLA TERAPI PADA PASIEN KANKER NASOFARING DI RSUD Prof. Dr. MARGONO SOEKARJO
DOI:
https://doi.org/10.30595/pji.v9i2.707Abstract
ABSTRAK Penanggulangan kanker nasofaring sampai saat ini menjadi suatu masalah, gejala yang tidak spesifik dan letak nasofaring yang tersembunyi mengakibatkan keterlambatan dalam diagnosa yang akan mempengaruhi keberhasilan terapi dan prognosis yang buruk. Keberhasilan terapi yang tinggi dan kelangsungan hidup jangka panjang hanya terjadi pada kanker stadium awal dibandingkan stadium akhir. Memberikan gambaran pola terapi pada pasien kanker nasofaring di RSUD Prof. Dr. Margono Soekarjo (RSMS). Mendapatkan gambaran jenis obat kanker yang digunakan pada pasien kanker nasofaring di RSMS. Jenis penelitian ini adalah penelitian observasional dengan rancangan penelitian adalah cross sectional deskriptif dan metode pengambilan data secara retrospektif melalui rekam medik pasien. Sampel penelitian 199 pasien dengan perbandingan laki-laki dan perempuan 2,6:1, rata-rata umur pasien kanker nasofaring adalah 49,06±1,49 tahun (kisaran : 5-82th). Pasien datang ke RSMS kebanyakan sudah stadium lanjut (III dan IV) (30,1%). Sebanyak 143(71,6%) pasien mendapat terapi kanker dan 56(28,1%) pasien tidak mendapatkan terapi kanker. Terapi yang digunakan pada setiap stadium berbeda. Terdapat 3 jenis terapi yang digunakan di RSMS yaitu radioterapi 89(62,2%), kemoterapi 33(23,1%) dan kemoradiasi 21(14,7%). Golongan obat kanker yang digunakan adalah golongan alkilator, taxan, antibiotik dan alkaloid vinka. Diketahui banyak pasien yang memiliki kelengkapan jumlah siklus dan penyinaran yang rendah. Penyakit penyerta yang paling banyak adalah anemia 11(22,5%) dan golongan obat lain yang paling banyak digunakan adalah golongan analgetik 107(74,6%). Berdasarkan stadium kanker radioterapi adalah terapi yang paling banyak digunakan. Obat yang paling banyak digunakan pada kemoradiasi dan kemoterapi adalah cisplatin. Kata kunci: kanker nasofaring, pola terapi. ABSTRACK Nasopharyngeal cancer prevention until now become a problem, because early symptoms are not spesific and hidden location of nasopharyngeal cause a delay to diagnosis that will affect therapeutic efficacy and poor prognisis. High therapeutic efficacy and long term survival only achieved for patient who have early stage than advanced stage. This research purpose to provide overview a treatment pattern of nasopharyngeal cancer patients in Prof. Dr. Margono Soekarjo hospital (RSMS) and provide overview of cancer drugs types used in patient with nasopharyngeal cancer in RSMS. The research is observational research with descriptive cross sectional research design and retrospective methods of data collection through the medical records of patients. The total study population was 199 patients with a ratio of male and female was 2,6:1, the average age of nasopharyngeal cancer patients was 49.06 ± 1,49 years old (range: 5-82th). Patients come to RSMS have advanced stage (III and IV) (30,1%). 143(71,6) patients received cancer therapy and 56(28,1%) patients without cancer therapy. Therapy used in each stage is different. Three types of therapy used in RSMS. There are radiotherapy 89(62,2%), chemotherapy 33(23,1%) and chemoradiation 21(14,7%). Class of cancer drugs used are alkilator, taxan, antibiotics and alkaloids vinca. The most of patient have low in completed chemotherapy cycle and number of radiotherapy. Patients with comorbidities most anemic 11(22,5%) patients and the drug classes most widely used analgesic 107(74,6%). Based on cancer stage, radiotherapy is more widely used. The most widely used drugs in chemotherapy and chemoradiation is cisplatin. Keywords: nasopharyngeal cancer, the pattern of treatment.References
NCCN] National Comperhensive Cancer Network,2011,Head and Neck Cancer. Clinical Practice Guidlines in Oncology.596-690
Abdulamir, A.S., Hafidz, R.R., Abdulmuhaemen, N., Abubakar, F., Abbas, K.A., 2008, The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types, BMC Public Health.8:400
Adham, M., Kurniawn, A.N., Muhtadi, A.I., Roezin, Averdi., H.B., Gondhowiardjo, S., et al., 2012, Nasopharyngeal Carcinoma in Indonesia: Epidemiologi, Incidence, Sign, and Symptoms at Presentation, Chin J Cancer. 31:185-196
Aziz, M.F, 2009, Ginecologycal Cancer in Indonesia, J. Gynecol Oncol.1:8-10
Bartsch, H., Ohoshima, H., Pignatelli, B., Calmels, S., 1992, Endogenously Formed N-nitroso Compunds and Nitrosating agent in Human Cancer Etiology Pharmacogenetics.2:272-7
Bolvilken, B., Flaten T.P., Zheng, C., 1997, Relations between Nasopharingeal Carcinoma and Magnesium ad other Alkaline Eart Element in Soils in China, Med Hypothesese.48(1):21-25
Brady, L.W., Heilmann, H .P., Mous, M., Nieder, C., 2010, Nasopharyngeal cancer Multidiciplinary Management; Editor. Jiade J.Lu.Jay, Sscoper.anne W.M Lee. London New York: Springer Heidel Berg Dordrecht
Brierley, J.D., Calton, P.A., O’Sullivan, B., Dancey, J.E., Dawling, A.J., Irish, J.C., et al, 2002. Accuracy of Recorder Tumor, Node, and Metastasis Stage in a Comperhensive Cancer Center. J Clin Oncol.20:413-419
Burkey, B.B., Ossoff., Robert, H., 1993, Endoscopy of Nasopharyngeal Cancer, Diagn Ther Endosc.1:63-68
Cathryn, E.T., Liavaag, G., Jeremy, L., Freeman., Jonatan, K.D.P., Roy, K., et al, 1999. Nasopharyngeal Brush Biopsies and Detection of Nasopharyngeal Cancer in a High Risk Population, J Natl Cancer Inst.91:796-800
Cepeda, V., Fuertes, M.A., Alonso, C., Castilla, J., Quevedo, C., Perez,J.M., 2007, Biochemical Mechanisms of Cisplatin Cytotoxity. Anticancer Agents Med Chem. 7:3-18
Chan, A.T., Gregoire, V., Lefabvre, J.L., Licitra, L., 2010, Clinical Practice Guideline Nasopharingeal Cancer: EHNS-ESMO-ESTRO Clinical Practice Guideline for Diagnosis, Treatment and Follow Up, Annals of Oncology.21:v187-v189
Chan, A.T.C., Teo, P.M.L., Ngan, R.K., Leung, T.W., Lau, W.H., Zee, B., et al., 2002, Concurrent Chemoterapy-Radiotherapy Compared with Radiotherapy Alone in Loceregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of Phase III Randomized Trial, J Clin Oncol. 20:2038-2044
Chan, A.T.C., Teo, P.N.L., Leung, T.W.T., Johnson, P.J., 1998, The Role of Chemotherapy in the Management of Nasopharyngeal Cancer, Cancer. 82:1003-12
Chang, E.T., Adami, H.O., 2006, The Enigmatic Epidemiology of Nasopharyngeal Carcinoma, Cancer Epidemiology Biomarkers prev.15: 1765-1777
Chen, Y., Tsang, N.M., Tseng, C.K., Lin, S.Y., 2000, Causes of Interruption of Radiotherapy in Nasopharyngeal Carcinoma Patient in Taiwan, Jpn J Clin Oncol.30:230-234
Chua, D.T.T., Sham, J.S.T., Kwong, D.L.W., Au, G.K.H., 2003, Treatment Outcome after Radiotherapy Alone for Patient with Stage I-II Nasopharyngeal Carcinoma, Cancer. 98:74-80
Dahlan, S., 2005, Besar Sampel Dalam Penelitia Kedokteran dan Kesehatan, Jakarta, Arkans
Davey, P., 2006, At a Glance Medicine, Jakarta, Gelora Aksara Pratama
Dechamphunkul, T., Pruegsanusak, K., Sangthawan, D., Sunpaweravong, P., 2011, Concurent Chemoradiotherapy with Carpoplatin Followed by Carboplatin and 5-Flourouracil in Locally Advanced Nasopharyngeal carcinoma, Head Neck Oncol.3:30
Dorland, W.A., Newman., 2002, Kamus Kedokteran Dorland. Edisi 29, Jakarta, EGC
Fountzilas, G., Bamias, A., Fountzila, A.K., Karayannopoulou, G., Bobos, M., Athanasiou, E., et al,2009, Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in atient with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck. Anticancer Research.29:529-538
Gao, J., Hu, J.Y., Xia, F.F., Tao, Y.L., Li, G., 2010, Continous fall in hemoglobin level is a poor prognostic factor in patient with nasopharyngeal carcinoma treated with radiotherapy. Chin J Cancer.29:561-566
Herdini, C., Hutajulu, S., Indrasari, S.R., Hariwiyan, B., Fachiro, J., Mubarika, S., et al, 2011. Uji Serologi IgA Karakter KNF EBNA+VCA p-18 pada Penderita Keluhan Kronis Kepala Leher.1-10
Ho, F.C.H., Tham, I.W.K., Earnest, A., Lee, K.M., Lu, J.J., 2012, Pattern of Regional Lymph Node Metastasis of Nasopharyngeal Carcinoma : A Meta-analysis of Clinical Evidence, BMC Center.12:98
Hoe, J., 1989, CT of Nasopharyngeal Carcinoma: Significance of Widening of the Preoccipital Soft Tissue on Axial Scan. AJR. 153:867-872
Jemal, A., Bray, F., Melissa, M., Ferlay, J.M.E., Ward, E., Forma,D., et al, 2011, Global Cancer Statistic, CA Cancer J Cun.61:69-90
Jost, L., Roila, F., 2010, Management of Cancer Pain:ESMO Clinical Practice Guideline. Ann Oncol. 5: 257-260
King, A.D., Vlantis, A.C., Tsang, R.Y.Y., Gary, T.M.K., 2006, Magnetic Resonance Imaging for The Detection of Nasopharingeal Carcinoma, Am J Neuroradiol. 27:1288-1291
Kong, I.S., Yang, Y.S., Choi, D.I., Kwon, S.H., Hong, K.H, 2008, The Effect of Induction Chemotherapy Using Docetaxel and Platinum in Treatment Methods of Nasopharyngeal Carcinoma, Korean J Otorhinolaryngol-Head Neck Surg. 51: 58-63
Kurnianda, J., Wiyadi, N., Wulaningsih, W., 2008, Risk of anemia in head and neck cancer patient undergoing chemotherapy with high-dose cisplatin, Med J Indones. 17:248-54
Kwong, D.L.W., Sham, J.S.T., Au, G.K.H., Chua, D.T.T., Kwong, P.W.K., Cheng, A.C.K., 2004, Concurrent and Adjuvant Chemotherapy for Nasopharyngeal Carcinoma: a Factorial Study. J Clin Oncol.14:26643-53
Lin, J.C., Jan, J.S., Hsu, C.Y., Liang, W.M., Jiang, R.S., Wang, W.Y., 2003, Phase III Study of Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Nasopharyngeal Carcinoma: Postive Effect on Overall and Progression-Free Survival, J Clin Oncol.21:631-637
Ludwig, J.A., Weinstein, J.N., 2005, Biomarkers in Cancer Staging, Prognososis and Treated Selection, Nature. 5:845-856
Marcial, V.A., Pajak, T.F., Mohiuddin, M.,Cooper, J.S., Al-Sharraf, M.,Mowry, P.A., et al., 1990., Commitant Cisplatin Chemotherapy and Radiotherapy in advanced Mucosal Squamous Cell Carcinoma of the Head and Neck, Cancer.66:1861-6
Marzaini, D.S., Tobing, D.L., Kresno, S.B., Gondhowiardjo, S., 2009, The Accuracy of Plasma EBV-DNA Quantification Using LMP2 as Primer to Detect Distance Metastasis After Radiation of Nasopharyngeal Cancer in “Dharmais” National Cancer Center, Indonesian Jurnal of Cancer.3:47-51
Mould, R.F., Tai, H.P., 2002, Nasopharyngeal Carcinoma: Treatments and Outcomes in The 20th Century, Br J Radiol.75:307-339
Nafrialdi., Sulistia, G., editor, 2007, Farmakologi dan Terapi. Edisi 5. Jakarta: Bagian Farmakologi FK IU
Notoatmodjo, S., 2010, Metodelogi Penelitian Kesehatan Edisi revisi, Jakarta, Rineka Cipta
Parkin, D.M., Whelan, S.L., Ferlay, J., Teppo, L., Thomas, D.B., 2002, Cancer Incidence In Five Continents. IARC Sci Publ.8:155
Rajhi, N.A., Sebaie, Y.E., Khafaga, Y., Alzahrani, A., Mohamed, G., Amro, A.A., 2009, Nasopharyngeal carcinoma in Saudi Arabia: Clinical Presentation and Diagnostic Delay, East Mediterr Health J. 15:1301-1307
Rossi, A., Molinasari, R., Boracchi, P., Vencchio, M.D., Marubini, E., Nava, M., et al.,1988, Adjuvant Chemotherapy with Vincristine, Cyclophosphamide, and Doxorubicin after Radiotherapy in Local Regional Nasopharyngeal Cancer: Result of a 4 year Multicenter Randomized Study. JCO.6: 1401-1410
Sharma, T.D., Sigh, T.T., Laishram, R.S., Sharma, L.D.C., Sunita, A.K., Imchen, L.T., 2011, Nasopharyngeal Carcinoma –a Clinico- Phatological Study in a Regional Cancer Centre of Northeastern India, Asian Pasific J Cancer Prev. 12:1583-1587
Siregar, C.J.P., 2003, Farmasi Rumah Sakit: Teori dan Penerapan, Jakarta, buku kedokteran EGC
Soewito, M., Kadir, A., Savitri, E., Bahar, B., 2010, Respons antibodi IgA terhadap epstein-Barr (EBV) pada keluarga penderita Kanker Nasofaring.1-11
Stevenson, M., Harris, J.M.D., 2011, Nasopharyngeal Cancer Treatment Protocols. Medscape Reference.1-5
Susworo, R., 2004., Kanker Nasofaring epidemiologi dan Pengobatan Mutahir, CDK.144:16-8
Tan, E.H., Khoo, K.S., Fong, K.W., Lee, K.S., Lee, K.M., Chua, E.T., et al.1999. Phase II Trial of a Paclitaxel and Carboplatin Combination and asian Patient with Metastatic Nasopharingeal Carcinoma. Ann Oncol.10:235-237
Tanvetyanon, T., Pandya, T., McCaffrey, J., Zhu, W., Boulware, D., DeConti, Trotti, A., 2009, Prognostic Factor for Survival After Salvage Reirradiation of Head and Neck Cancer, J Clin Oncol. 27: 1983-1991
Vaughan, T.L., Shapiro, J.A., Burd, R.D., Swanson, G.M., Berwick, M., Lynch, C.F., et al.1996. Nashoparyngeal Cancer in a Low Risk Population : Defining Risk Factors by Histological Type. Cancer Epidemiol Biomarkers Prev.5:587-93
Vaughan, T.L., Stewart, A.P., Tesch,Key., L, Charles, F., Swanson, G.M., Lyon, J.L., Berwick,Marianne., 2000, Occupational Expossure to Formaldehyd dust and nasopharyngeal Carcinoma,Occup Environ Med.57:376-387
Wee, J., Tan, E.H., Tai, B.C., Leong, S.S., Tan, T., Chua, E.T., et al., 2005, Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patient with American Joint Commitee on Cancer/International Union Againt Cancer Stage III and IV Nashoparyngeal Cancer of the Endemic Variety, J Clin Oncol.23:6730-6738
Wildeman, M.A.M., Heike, J.N., Baris, K., Bing, I.T., 2009, Photodinamic Therapy in The Therapy for recurrent/Persistent Nashoparyngeal Cancer, BMC .1:40
Wiliyanto, O., 2006, Insidensi Kanker Kepala Leher Berdasarkan Diagnosis Patologi Anatomi di RS Dr Kariadi Semarang periode 1 Januari 2011-31 Desember 2005, Artikel Penelitian [terhubung berkala]. Eprint.undip.ac.id/20998/1/Onggo.pdf [7 November 2011]
Yang, X.R., Diehl, S., Preiffer, R., Chen, C.J., Hsu, W.L.Dosemeci, M., et al.,2005, Evaluation of Risk factors for Nasopharingeal Carcinoma in High-risk Nasopharyngeal Carcinoma Families in Taiwan, Cancer Epidemiol Cancer Prev.14:5-900
Yurnadi., Suryandari, D.A., Soeharso, P., Moeloek, N., Susworo, R., 2010, Pola Distribus Alotip Gen Polymeric Immunoglobulin Receptor (PIGR) pada Penderita Karsioma Nasofaring (KNF) di Indonesia, Maj Kedokt Indon. 60:489-495
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
